Cancer Institute of New Jersey (CINJ), Division of Surgical Oncology, Gastrointestinal

Medicine & Life Sciences

1. Peritoneal Neoplasms 100%
2. Metallochaperones 83%
3. Oncologists 78%
4. Zinc 65%
5. Neoplasms 61%
6. Guidelines 57%
7. Peritoneal Diseases 50%
8. Liver 44%
9. Palliative Care 34%
10. Colorectal Neoplasms 33%
11. Pancreaticoduodenectomy 32%
12. Pharmacists 31%
13. Pathologists 31%
14. Drug Therapy 31%
15. Radiologists 31%
16. Neoplasm Metastasis 29%
17. Adenocarcinoma 28%
18. Yttrium-90 28%
19. Pancreatic Neoplasms 27%
20. Esophagectomy 27%
21. Radium 27%
22. Physicians 26%
23. Hepatic Artery 26%
24. Doxorubicin 23%
25. Survival 23%
26. NSC319726 22%
27. Neuroendocrine Tumors 21%
28. Therapeutics 20%
29. Hepatocellular Carcinoma 19%
30. Mesothelioma 19%
31. Neoadjuvant Therapy 18%
32. Liver Neoplasms 18%
33. Malignant Mesothelioma 17%
34. Breast Neoplasms 15%
35. Desmoplastic Small Round Cell Tumor 15%
36. Appendiceal Neoplasms 14%
37. Pharmaceutical Preparations 14%
38. Thiosemicarbazones 13%
39. Surgical Oncology 13%
40. Radiotherapy 13%
41. Databases 12%
42. Morbidity 12%
43. Mortality 12%
44. Infusion Pumps 12%
45. Gastrointestinal Neoplasms 11%
46. Chemoradiotherapy 11%
47. Pharmacokinetics 11%
48. Breast 11%
49. Gastrointestinal Stromal Tumors 11%
50. Copper 11%
51. gemcitabine 10%
52. Microspheres 10%
53. Systematic Reviews 10%
54. Patient Care 10%
55. Tea 10%
56. Stomach 10%
57. Metals 10%
58. Health Care Outcome Assessment 9%
59. Stomach Neoplasms 9%
60. Survival Analysis 9%
61. Parenteral Nutrition 9%
62. Odds Ratio 9%
63. Mutation 9%
64. Enteral Nutrition 8%
65. Malnutrition 8%
66. Ovarian Neoplasms 8%
67. Peliosis Hepatis 7%
68. bromobenzene 7%
69. Growth 7%
70. MAP4 7%
71. Cytokine Release Syndrome 7%
72. DNA 7%
73. Syndecan-4 7%
74. Colon 7%
75. Nutrition Policy 7%
76. Cohort Studies 7%
77. Mucous Membrane 7%
78. Heterografts 7%
79. Proteins 7%
80. Hydrazones 7%
81. Capecitabine 7%
82. Ions 7%
83. Esophageal Neoplasms 7%
84. Ionophores 7%
85. Retrospective Studies 6%
86. Nutritionists 6%
87. Radiation 6%
88. Credentialing 6%
89. Length of Stay 6%
90. Poxviridae 6%
91. Dinoprostone 6%
92. African Continental Ancestry Group 6%
93. Drug Discovery 6%
94. Propensity Score 6%
95. Nutrition Assessment 6%
96. Diaphragmatic Hernia 6%
97. Nivolumab 6%
98. Combined Vaccines 6%
99. Estrogen Receptors 6%
100. Vinorelbine 6%
101. Polyphenols 6%
102. Recurrence 6%
103. Financial Support 6%
104. Lipoxygenase 6%
105. Safety 6%
106. Unnecessary Procedures 6%
107. Mutant Proteins 6%
108. Esophagogastric Junction 6%
109. Rectal Neoplasms 5%
110. Comorbidity 5%
111. Acute-Phase Reaction 5%
112. Alleles 5%
113. Gene Editing 5%
114. Albumins 5%
115. Colorectal Surgery 5%
116. Carotenoids 5%
117. Wounds and Injuries 5%
118. Facilities and Services Utilization 5%
119. Microwaves 5%
120. Cannabinoids 5%
121. Certification 5%
122. Cholangiocarcinoma 5%
123. Clustered Regularly Interspaced Short Palindromic Repeats 5%
124. Frailty 5%
125. Clinical Trials 5%
126. Anal Canal 5%
127. Bevacizumab 5%
128. Hypercalcemia 5%
129. Peritoneal Cavity 5%
130. Sepsis 5%
131. Phenobarbital 5%
132. Optical Imaging 5%
133. Leukopenia 5%
134. Venous Thromboembolism 5%
135. Hemangioma 5%
136. Metformin 5%